Literature DB >> 1229063

Treatment of prostatic carcinoma with various types of estrogen derivatives.

G Jönsson, A M Olsson, W Luttrop, Z Cekan, K Purvis, E Diczfalusy.   

Abstract

Entities:  

Keywords:  Androgens; Biology; Cancer; Clinical Research; Contraception; Contraceptive Agents, Estrogen--therapeutic use; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents--therapeutic use; Diseases; Endocrine System; Estradiol--analysis; Estrogens--therapeutic use; Estrone--analysis; Ethinyl Estradiol--therapeutic use; Family Planning; Follicle Stimulating Hormone--analysis; Genitalia; Genitalia, Male; Gonadotropins; Gonadotropins, Pituitary; Hormones; Luteinizing Hormone--analysis; Neoplasms; Physiology; Pituitary Hormones; Progestational Hormones; Progesterone--analysis; Prolactin--analysis; Prostate; Research Methodology; Stanolone--analysis; Testosterone--analysis; Urogenital System

Mesh：

Substances：

Year:  1975        PMID： 1229063     DOI： 10.1016/s0083-6729(08)60965-6

Source DB:  PubMed          Journal:  Vitam Horm        ISSN： 0083-6729            Impact factor:   3.421


× No keyword cloud information.
  8 in total

1.  Circadian variation in systemic hormone levels in healthy men.

Authors:  B Sjöberg; B de la Torre; M Hedman; G Falkay; E Diczfalusy
Journal:  J Endocrinol Invest       Date:  1979 Apr-Jun       Impact factor: 4.256

Review 2.  [Problems and principles of hormone therapy of advanced prostate cancer].

Authors:  J E Altwein; P Faul
Journal:  Klin Wochenschr       Date:  1990-04-02

Review 3.  Steroid hormone receptors in the regulation of differentiation. A review.

Authors:  K S McCarty; K S McCarty
Journal:  Am J Pathol       Date:  1977-03       Impact factor: 4.307

4.  Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.

Authors:  S Eriksson; A Eriksson; R Stege; K Carlström
Journal:  Calcif Tissue Int       Date:  1995-08       Impact factor: 4.333

5.  Androgens during different modes of endocrine treatment of prostatic cancer.

Authors:  A Pousette; K Carlström; R Stege
Journal:  Urol Res       Date:  1989

Review 6.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

7.  Estrogen in patients with prostatic cancer. An assessment of the risks and benefits.

Authors:  P Henriksson
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 8.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.